特發性嗜睡症

Jazz Pharmaceuticals 將於 SLEEP 2026 會議上發表數據,重點介紹 Xywav 對發作性睡病及特發性嗜睡症的療效
Idiopathic Hypersomnia Narcolepsy Sleep Pharmaceuticals

Jazz Pharmaceuticals 將於 SLEEP 2026 會議上發表數據,重點介紹 Xywav 對發作性睡病及特發性嗜睡症的療效

Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place 六月 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]

Marry Murray Patient Voices Column with Project Sleep
Idiopathic Hypersomnia Patient Advocacy

Nap Roulette

My family loves to play games. One of the first things my husband and I bonded over was board games, and we passed that love of games to our children. As a family, we enjoy playing board games like Settlers of Catan and Carcassonne and card games like Dominion and […]

Idiopathic Hypersomnia Product & Vendor Updates Sleep Pharmaceuticals

Avadel’s LUMRYZ Receives FDA Orphan Drug Designation for Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may […]

xywave jazz narcolepsy cataplexy eds
Sleep Pharmaceuticals Idiopathic Hypersomnia

Jazz Presents Phase 3 Results of Xywav in Adults with Idiopathic Hypersomnia

Jazz Pharmaceuticals plc has announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the Clinical Trials Plenary Session of the 2021 American Academy of Neurology (AAN) Annual Meeting. The presentation will further […]